Severe Asthma ToolkitSevere Asthma Toolkit
HomeAboutSpecific PopulationsRegistriesContributorsContact
Twitter
  • What is Severe Asthma?
    • Overview
    • Definition
    • Prevalence & Burden
    • Pathophysiology
    • Symptoms
    • Severe Asthma Attacks / Exacerbations / Flare-ups
    • Asthma Phenotypes
  • Diagnosis & Assessment
    • Overview
    • Diagnosis Overview
    • Assessment Overview
    • Lung Function Assessments
    • Questionnaires
    • Allergy Assessments
    • Phenotyping
    • Bronchoscopy
    • Imaging
    • Occupational Asthma
  • Management
    • Overview
    • Asthma Education
      • About Severe Asthma
      • Asthma Pathophysiology
      • Medications Education
      • Self-Monitoring
      • Triggers
      • Review
    • Written Action Plans
    • Adherence
    • Inhaler Technique
    • Physical Activity & Exercise
    • Interdisciplinary Approach & Multidimensional Assessment
    • Referral
  • Medications
    • Overview
    • Relievers
    • Preventers / Controllers
    • Add-on Therapies
    • Monoclonal Antibodies
    • Bronchial Thermoplasty
  • Co-Morbidities
    • Overview
    • Pulmonary & Upper Airways
      • Allergic & Non-Allergic Rhinitis
      • Chronic Rhinosinusitis
      • Dysfunctional Breathing
      • Vocal Cord Dysfunction
      • Chronic Obstructive Pulmonary Disease
      • Bronchiectasis
      • Obstructive Sleep Apnoea
    • Extra-Pulmonary
      • Obesity
      • Anxiety & Depression
      • Gastro-oesophageal Reflux Disease (GORD)
      • Osteoporosis
      • Cardiovascular Disease & Metabolic Disease
  • Living with Severe Asthma
    • Overview
    • Daily Symptom Burden
    • Mental & Emotional Health
    • Intimacy & Relationships
    • Self-Management Support
    • Medication Use & Costs
    • Experience of Care
    • Experience of Asthma Attacks
    • Prognosis
  • Establishing a Clinic
    • Overview
    • Set-up
    • Staffing & Multidisciplinary Team Approach
    • Facilities
    • Delivery Approach
    • Tailored Referrals
    • Evaluation
    • Opportunities for Training & Research
    • Barriers & Hurdles
  • Paediatrics
    • Overview
    • Management in Paediatrics
    • Assessment in Paediatrics
    • Alternative Diagnosis & Co-Morbidities in Paediatrics
    • Psychosocial Issues in Paediatrics
    • Medications in Paediatrics
    • Asthma in the Adolescent Population
  • Resources
    • Overview
    • Clinic Recommendations
    • Infographics
    • Asthma Assessment Resources
    • Systematic & Multidimensional Assessment Resources
      • Airway Components
      • Comorbidity Components
      • Risk Factor Components
    • Translation & Implementation
    • Case Studies
    • Presentations
    • Videos
    • Relevant Links
    • Key References

Australian Mepolizumab Registry (AMR)

Home Registries Australian Mepolizumab Registry (AMR)

Australian Mepolizumab Registry (AMR)

The Australian Mepolizumab Registry (AMR) is an investigator-initiated, observational post-marketing surveillance registry of patients with severe refractory eosinophilic asthma undergoing mepolizumab (Nucala) therapy in Australia. Mepolizumab is a monoclonal antibody therapy that blocks the binding of interleukin-5 (IL-5) to its receptor, reducing the production and survival of eosinophils.

In clinical trials, mepolizumab treatment reduced hospitalisations by approximately 50% and has been demonstrated to have an oral-steroid sparing effect. Following mepolizumab’s approval in Australia, the AMR will assess the effects of mepolizumab in “real-world” conditions.

For more information on the use of mepolizumab treatment in the clinic see our Mepolizumab Clinic Recommendations document.

The AMR was established in January 2017.  It is managed by the Australasian Severe Asthma Network (ASAN), sponsored by the Hunter New England Local Health District and coordinated in Newcastle, NSW Australia. Human research ethics committee and local research governance approvals are in place for the conduct of this registry.

 The main purposes of the AMR are to:

  1. Enable clinicians to document eligibility for mepolizumab treatment commencement and continuation,
  2. Document drug-related adverse effects and severe adverse events,
  3. Report on the magnitude of the problem of severe eosinophilic asthma, characteristics of this population and their management.

Patient enrolment

Clinicians are invited to enrol patients eligible for treatment with mepolizumab within the Pharmaceutical Benefits (PBS)-subsidised scheme and outside of the scheme.  Ideally, patients are registered prior to commencement of mepolizumab treatment, however retrospective registration is possible.

Information on mepolizumab eligibility requirements and initiation application forms is available on the Services Australia website.

Data collection

If you would like to register your interest or for further information, contact:

Dr Erin Harvey
Australasian Severe Asthma Network
Email: erin.harvey@newcastle.edu.au
Phone: +61 2 4042 0099

Dr. Harvey can provide information on enrolling patients in the AMR, data collection and can assist with site-specific ethics and local governance requirements.

The AMR is supported by the GlaxoSmithKline Investigator-Sponsored Study scheme.

Previous
Next

Last Updated on October 18, 2022

Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories

More results...

  • Australasian Severe Asthma Registry
  • Australian Mepolizumab Registry (AMR)
  • Australian Xolair Registry (AXR)

We want to know who accesses the Severe Asthma Toolkit and how it is used. Please complete our survey.

Responses will inform the continued development of the Severe Asthma Toolkit and future translation and implementation activities. Any feedback you provide will be greatly appreciated.

Complete Survey

  • Website Terms of Use
  • Website Survey
© Copyright 2018    CRICOS Provider Number 00109J    The University of Newcastle, Australia